Convergen has secured a $10 million Seed financing round to accelerate the development of its TrimTAC targeted protein degradation platform, designed to eliminate pathogenic multimeric protein aggregates linked to neurodegenerative diseases. The funding was led by Qiming Venture Partners, a global venture capital firm focused on life sciences and healthcare innovation.
The company plans to deploy the new capital to advance its proprietary TrimTAC technology, which leverages the TRIM21 E3 ubiquitin ligase to enable selective degradation of protein aggregates that traditional bifunctional degraders have been unable to target effectively. The investment will also support progress across Convergen’s early clinical pipeline and expansion of its scientific and drug development capabilities.
Convergen’s scientific foundation is anchored by research contributions from Scientific Co-Founder Dr. Ting Han, whose work includes elucidating the mechanism of action for RBM39 degraders and pioneering TRIM21-based molecular glue degraders. Co-Founder Dr. Jinquan Sun said the financing marks an important step toward clinical validation of TrimTAC as the company expands work in neurodegeneration and other diseases with significant unmet need.
Qiming Venture Partners said the platform has the potential to overcome a critical limitation in targeted protein degradation by enabling selective clearance of multimeric aggregates. This area has hindered progress in developing transformative treatments for neurodegenerative disorders. The investor highlighted Convergen’s scientific leadership and experienced team as key strengths in advancing next-generation protein degradation therapies.
Convergen develops bifunctional degraders that apply TRIM21 to selectively clear pathological multimeric proteins implicated in neurodegenerative and other severe diseases. Qiming Venture Partners, founded in 2006, manages 18 funds across USD- and RMB-denominated vehicles and has invested in more than 580 companies globally.
KEY QUOTES:
“The seed financing—led by Qiming Venture Partners—validates TrimTAC’s potential to redefine treatment for diseases caused by pathogenic multimeric proteins. Together with Qiming, we will expand our expertise in TPD and CNS drug development, accelerate our pipeline toward clinical proof-of-concept, and deliver on our mission to help patients with limited treatment options.”
Dr. Jinquan Sun, Co-Founder of Convergen
“Convergen’s TrimTAC platform addresses a critical gap in TPD—selective degradation of multimeric aggregates—that has held back progress in neurodegenerative diseases. The company’s world-class scientific foundation combined with its veteran leadership team, positions it to become a leader in advancing the next-generation protein degradation. We are proud to partner with Convergen and support its journey to bring transformative therapies to patients.”
Dr. Kan Chen, Partner and Co-Lead of Healthcare at Qiming Venture Partners
